Impact BioMedical Shareholders Approve Zoar Merger With 99.97% of Votes Cast
IBO has more than doubled off its 52-week low of $2.43.
Summary
Impact BioMedical stockholders voted overwhelmingly to approve the Zoar Limited merger at the November 13, 2026 special meeting, clearing the shareholder hurdle for a deal the cash-strapped company has called its main path forward.
Key Events · M&A and Partnerships · IBO
-
Zoar Merger Approved by Shareholders
Stockholders approved and adopted the Merger and Share Exchange Agreement with Zoar Limited (f.k.a. Dr Ashleys Limited) by a vote of 7,713,011 for, 2,002 against and 197 abstain.
-
Quorum and Turnout
At the Special Meeting, 7,715,210 shares were represented — 89.29% of the 8,640,000 shares outstanding and eligible to vote on the October 13, 2026 record date.
-
New Board and Charter Adopted
Stockholders approved the Amended and Restated Memorandum and Articles of Association (7,600,533 for, 114,489 against) and elected eight directors: Frank D. Heuszel, Elise Brownell, Melissa Sims, Castel Hibbert, David Keene, Christian Zimmerman, Jason Grady and Chan Heng Fai Ambrose.
-
Auditor and Say-on-Pay Ratified
Grassi & Co. Certified Public Accountants, P.C. was ratified as independent auditor for fiscal year 2026 (7,712,827 for), and named executive officer compensation passed on an advisory basis (7,506,873 for, 208,159 against).
Analysis · IBO · Life Sciences
The vote clears the last major shareholder hurdle for a deal in the works since June 2025 and the company's stated path out of its going-concern warning. With only $21,000 of cash reported at September 30, 2026, Impact BioMedical needs the Zoar combination to close to keep operating. The margin was overwhelming — 7,713,011 for versus 2,002 against — so the remaining risk is execution and closing, not shareholder approval. The same meeting also seated an eight-person board and ratified Grassi & Co. as auditor for 2026, putting the post-merger governance structure in place.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IBO was trading at $6.17 on NYSE in the Life Sciences sector, with a market capitalization of approximately $53.3M. The 52-week trading range was $2.43 to $10.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.